Concepts (181)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Lung Neoplasms | 26 | 2021 | 12040 | 1.170 |
Why?
|
| Pleural Effusion | 1 | 2023 | 228 | 0.750 |
Why?
|
| Diagnostic Imaging | 4 | 2021 | 1173 | 0.610 |
Why?
|
| Radiography, Thoracic | 4 | 2019 | 477 | 0.610 |
Why?
|
| Positron-Emission Tomography | 3 | 2018 | 2198 | 0.600 |
Why?
|
| Thoracic Neoplasms | 3 | 2016 | 363 | 0.580 |
Why?
|
| Tomography, X-Ray Computed | 14 | 2019 | 7786 | 0.570 |
Why?
|
| Postoperative Complications | 6 | 2021 | 5679 | 0.560 |
Why?
|
| Diagnostic Errors | 3 | 2018 | 518 | 0.540 |
Why?
|
| Mediastinum | 5 | 2019 | 276 | 0.520 |
Why?
|
| Radiography | 2 | 2018 | 1993 | 0.520 |
Why?
|
| Lung | 16 | 2021 | 3288 | 0.490 |
Why?
|
| Smoking | 3 | 2014 | 2555 | 0.480 |
Why?
|
| Postoperative Care | 1 | 2017 | 727 | 0.440 |
Why?
|
| Pneumonectomy | 2 | 2018 | 862 | 0.430 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 7 | 2020 | 5581 | 0.420 |
Why?
|
| Immunotherapy, Adoptive | 1 | 2022 | 1852 | 0.390 |
Why?
|
| Tobacco Smoke Pollution | 1 | 2012 | 112 | 0.380 |
Why?
|
| Solitary Pulmonary Nodule | 3 | 2018 | 125 | 0.340 |
Why?
|
| Mass Screening | 2 | 2014 | 1554 | 0.330 |
Why?
|
| Multidetector Computed Tomography | 3 | 2017 | 147 | 0.270 |
Why?
|
| Diagnosis, Differential | 8 | 2023 | 4838 | 0.250 |
Why?
|
| Immunotherapy | 4 | 2020 | 3559 | 0.250 |
Why?
|
| Neoplasm Staging | 4 | 2020 | 14020 | 0.250 |
Why?
|
| Small Cell Lung Carcinoma | 2 | 2021 | 417 | 0.240 |
Why?
|
| Mediastinal Neoplasms | 2 | 2018 | 427 | 0.220 |
Why?
|
| Societies, Medical | 5 | 2020 | 1320 | 0.220 |
Why?
|
| Ipilimumab | 2 | 2019 | 765 | 0.220 |
Why?
|
| Pleural Neoplasms | 2 | 2018 | 485 | 0.220 |
Why?
|
| Magnetic Resonance Imaging | 3 | 2019 | 7900 | 0.210 |
Why?
|
| Humans | 45 | 2023 | 271093 | 0.200 |
Why?
|
| Benzimidazoles | 2 | 2021 | 437 | 0.180 |
Why?
|
| Radiosurgery | 3 | 2019 | 1384 | 0.180 |
Why?
|
| Radiologists | 1 | 2022 | 179 | 0.170 |
Why?
|
| Evidence-Based Medicine | 6 | 2020 | 1036 | 0.160 |
Why?
|
| Cell- and Tissue-Based Therapy | 1 | 2022 | 383 | 0.160 |
Why?
|
| Antibodies, Monoclonal, Humanized | 2 | 2020 | 3416 | 0.160 |
Why?
|
| Etoposide | 1 | 2021 | 907 | 0.160 |
Why?
|
| Respiratory Tract Diseases | 1 | 2018 | 111 | 0.150 |
Why?
|
| Radiography, Dual-Energy Scanned Projection | 1 | 2018 | 57 | 0.150 |
Why?
|
| Carboplatin | 1 | 2021 | 880 | 0.150 |
Why?
|
| Intensive Care Units | 2 | 2012 | 736 | 0.140 |
Why?
|
| Bronchial Neoplasms | 1 | 2017 | 82 | 0.140 |
Why?
|
| Positron Emission Tomography Computed Tomography | 2 | 2019 | 881 | 0.130 |
Why?
|
| Fibrosis | 1 | 2019 | 716 | 0.130 |
Why?
|
| Heart Neoplasms | 1 | 2018 | 209 | 0.130 |
Why?
|
| Antineoplastic Agents, Immunological | 3 | 2020 | 1338 | 0.130 |
Why?
|
| United States | 7 | 2020 | 15891 | 0.130 |
Why?
|
| Dyspnea | 1 | 2018 | 420 | 0.130 |
Why?
|
| Respiratory Tract Infections | 1 | 2019 | 408 | 0.120 |
Why?
|
| Radiographic Image Enhancement | 2 | 2015 | 410 | 0.120 |
Why?
|
| Taxes | 1 | 2014 | 5 | 0.120 |
Why?
|
| Immunocompromised Host | 1 | 2019 | 719 | 0.120 |
Why?
|
| History, 16th Century | 1 | 2014 | 31 | 0.120 |
Why?
|
| History, 17th Century | 1 | 2014 | 38 | 0.120 |
Why?
|
| Early Detection of Cancer | 4 | 2018 | 1344 | 0.120 |
Why?
|
| History, 18th Century | 1 | 2014 | 89 | 0.120 |
Why?
|
| Lung Diseases | 1 | 2020 | 751 | 0.120 |
Why?
|
| Thoracic Wall | 1 | 2016 | 188 | 0.120 |
Why?
|
| History, 19th Century | 1 | 2014 | 146 | 0.120 |
Why?
|
| Adenocarcinoma | 1 | 2012 | 7919 | 0.110 |
Why?
|
| Smoking Prevention | 1 | 2014 | 144 | 0.110 |
Why?
|
| Multimodal Imaging | 2 | 2015 | 550 | 0.110 |
Why?
|
| Empyema | 1 | 2013 | 37 | 0.110 |
Why?
|
| Respiratory Tract Fistula | 1 | 2013 | 34 | 0.110 |
Why?
|
| Bronchial Fistula | 1 | 2013 | 37 | 0.110 |
Why?
|
| Heart, Artificial | 1 | 2014 | 69 | 0.110 |
Why?
|
| Pulmonary Edema | 1 | 2013 | 81 | 0.110 |
Why?
|
| Pleural Diseases | 1 | 2013 | 58 | 0.110 |
Why?
|
| Radiographic Image Interpretation, Computer-Assisted | 2 | 2014 | 382 | 0.110 |
Why?
|
| Radon | 1 | 2012 | 14 | 0.100 |
Why?
|
| History, 21st Century | 1 | 2014 | 420 | 0.100 |
Why?
|
| Vascular Diseases | 1 | 2015 | 235 | 0.100 |
Why?
|
| Catheterization, Swan-Ganz | 1 | 2012 | 17 | 0.100 |
Why?
|
| History, 20th Century | 1 | 2014 | 545 | 0.100 |
Why?
|
| Multiple Pulmonary Nodules | 1 | 2013 | 60 | 0.100 |
Why?
|
| Intubation | 1 | 2012 | 43 | 0.100 |
Why?
|
| Thoracotomy | 1 | 2013 | 218 | 0.100 |
Why?
|
| Intra-Aortic Balloon Pumping | 1 | 2012 | 49 | 0.100 |
Why?
|
| Prosthesis Implantation | 1 | 2014 | 242 | 0.100 |
Why?
|
| Chemoradiotherapy | 1 | 2020 | 2028 | 0.100 |
Why?
|
| Thoracic Surgical Procedures | 1 | 2015 | 260 | 0.100 |
Why?
|
| Chest Tubes | 1 | 2012 | 119 | 0.090 |
Why?
|
| Coronary Angiography | 1 | 2014 | 536 | 0.090 |
Why?
|
| Liver Neoplasms | 2 | 2019 | 4826 | 0.090 |
Why?
|
| Air Pollutants | 1 | 2012 | 135 | 0.090 |
Why?
|
| Occupational Exposure | 1 | 2012 | 248 | 0.090 |
Why?
|
| Risk Factors | 3 | 2018 | 17911 | 0.090 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2017 | 1270 | 0.090 |
Why?
|
| Pacemaker, Artificial | 1 | 2012 | 208 | 0.080 |
Why?
|
| Defibrillators, Implantable | 1 | 2012 | 227 | 0.080 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 3 | 2021 | 16720 | 0.080 |
Why?
|
| Tracheostomy | 1 | 2012 | 254 | 0.080 |
Why?
|
| Catheterization, Central Venous | 1 | 2012 | 363 | 0.080 |
Why?
|
| Radiotherapy | 1 | 2015 | 1858 | 0.080 |
Why?
|
| Smoking Cessation | 1 | 2014 | 776 | 0.080 |
Why?
|
| Socioeconomic Factors | 1 | 2012 | 1270 | 0.080 |
Why?
|
| Phantoms, Imaging | 1 | 2014 | 1330 | 0.070 |
Why?
|
| Radiation Injuries | 1 | 2015 | 1475 | 0.070 |
Why?
|
| Molecular Targeted Therapy | 1 | 2018 | 2395 | 0.070 |
Why?
|
| Reproducibility of Results | 2 | 2015 | 6191 | 0.070 |
Why?
|
| Sex Factors | 1 | 2012 | 2186 | 0.070 |
Why?
|
| Antineoplastic Agents | 2 | 2021 | 14636 | 0.070 |
Why?
|
| Prevalence | 1 | 2014 | 3412 | 0.070 |
Why?
|
| Lymphoma | 1 | 2014 | 1516 | 0.060 |
Why?
|
| Middle Aged | 11 | 2021 | 90524 | 0.060 |
Why?
|
| Sensitivity and Specificity | 3 | 2019 | 5165 | 0.060 |
Why?
|
| Double-Blind Method | 2 | 2021 | 2585 | 0.060 |
Why?
|
| Acute Disease | 2 | 2019 | 2492 | 0.060 |
Why?
|
| Bevacizumab | 2 | 2018 | 967 | 0.060 |
Why?
|
| Male | 12 | 2021 | 128484 | 0.060 |
Why?
|
| Adult | 9 | 2021 | 82174 | 0.050 |
Why?
|
| Heart-Assist Devices | 1 | 2012 | 1041 | 0.050 |
Why?
|
| Combined Modality Therapy | 3 | 2019 | 9039 | 0.050 |
Why?
|
| Contrast Media | 2 | 2019 | 1500 | 0.050 |
Why?
|
| Aged, 80 and over | 5 | 2021 | 31079 | 0.050 |
Why?
|
| Aged | 8 | 2021 | 73550 | 0.050 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2017 | 4965 | 0.050 |
Why?
|
| Female | 11 | 2021 | 149120 | 0.050 |
Why?
|
| Heart Failure | 1 | 2014 | 2322 | 0.050 |
Why?
|
| Child | 1 | 2022 | 30596 | 0.040 |
Why?
|
| Treatment Outcome | 5 | 2021 | 33808 | 0.040 |
Why?
|
| Neoplasm Metastasis | 2 | 2020 | 5317 | 0.040 |
Why?
|
| Thorax | 1 | 2021 | 232 | 0.040 |
Why?
|
| Sclerosing Solutions | 1 | 2019 | 27 | 0.040 |
Why?
|
| Radiation Dosage | 2 | 2014 | 1042 | 0.040 |
Why?
|
| Postoperative Period | 1 | 2021 | 666 | 0.040 |
Why?
|
| Lymphatic Metastasis | 2 | 2019 | 4969 | 0.040 |
Why?
|
| Arginine Vasopressin | 1 | 2018 | 66 | 0.040 |
Why?
|
| Dose-Response Relationship, Radiation | 1 | 2019 | 751 | 0.040 |
Why?
|
| DNA Modification Methylases | 1 | 2018 | 176 | 0.040 |
Why?
|
| Poly (ADP-Ribose) Polymerase-1 | 1 | 2018 | 162 | 0.040 |
Why?
|
| Pleura | 1 | 2018 | 130 | 0.040 |
Why?
|
| Placebos | 1 | 2018 | 442 | 0.040 |
Why?
|
| Image-Guided Biopsy | 1 | 2019 | 336 | 0.030 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2015 | 10400 | 0.030 |
Why?
|
| DNA Repair Enzymes | 1 | 2018 | 238 | 0.030 |
Why?
|
| Erlotinib Hydrochloride | 1 | 2018 | 398 | 0.030 |
Why?
|
| Clinical Trials, Phase I as Topic | 1 | 2019 | 624 | 0.030 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2019 | 694 | 0.030 |
Why?
|
| Prognosis | 3 | 2019 | 22529 | 0.030 |
Why?
|
| Antineoplastic Agents, Alkylating | 1 | 2018 | 605 | 0.030 |
Why?
|
| Radiology | 1 | 2019 | 426 | 0.030 |
Why?
|
| Neoplastic Cells, Circulating | 1 | 2018 | 637 | 0.030 |
Why?
|
| Chronic Disease | 1 | 2018 | 1823 | 0.030 |
Why?
|
| Neoplasms | 1 | 2019 | 15933 | 0.030 |
Why?
|
| Quinazolines | 1 | 2017 | 956 | 0.030 |
Why?
|
| DNA Mutational Analysis | 1 | 2018 | 2357 | 0.030 |
Why?
|
| Algorithms | 2 | 2014 | 3904 | 0.020 |
Why?
|
| False Positive Reactions | 1 | 2013 | 376 | 0.020 |
Why?
|
| Heart | 1 | 2018 | 1172 | 0.020 |
Why?
|
| Thymus Neoplasms | 1 | 2017 | 416 | 0.020 |
Why?
|
| Biopsy | 1 | 2019 | 3488 | 0.020 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2016 | 1046 | 0.020 |
Why?
|
| Prosthesis Design | 1 | 2014 | 654 | 0.020 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2019 | 2663 | 0.020 |
Why?
|
| Promoter Regions, Genetic | 1 | 2018 | 3204 | 0.020 |
Why?
|
| Young Adult | 2 | 2019 | 22293 | 0.020 |
Why?
|
| Pyridines | 1 | 2017 | 1313 | 0.020 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2018 | 1900 | 0.020 |
Why?
|
| Flow Cytometry | 1 | 2016 | 3042 | 0.020 |
Why?
|
| Practice Guidelines as Topic | 1 | 2019 | 2403 | 0.020 |
Why?
|
| ErbB Receptors | 1 | 2018 | 2375 | 0.020 |
Why?
|
| Severity of Illness Index | 1 | 2019 | 4392 | 0.020 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2016 | 1658 | 0.020 |
Why?
|
| Pyrazoles | 1 | 2017 | 1551 | 0.020 |
Why?
|
| Survival Analysis | 1 | 2019 | 9290 | 0.020 |
Why?
|
| Biomarkers, Tumor | 2 | 2018 | 10714 | 0.020 |
Why?
|
| DNA Methylation | 1 | 2018 | 2770 | 0.020 |
Why?
|
| Pneumonia | 1 | 2013 | 794 | 0.020 |
Why?
|
| Immunohistochemistry | 1 | 2018 | 7645 | 0.020 |
Why?
|
| Nuclear Proteins | 1 | 2018 | 3435 | 0.020 |
Why?
|
| Liver | 1 | 2016 | 3063 | 0.020 |
Why?
|
| Critical Illness | 1 | 2012 | 740 | 0.020 |
Why?
|
| Survival Rate | 1 | 2019 | 12535 | 0.020 |
Why?
|
| Prospective Studies | 1 | 2019 | 13445 | 0.010 |
Why?
|
| Follow-Up Studies | 1 | 2019 | 15282 | 0.010 |
Why?
|
| Clinical Trials as Topic | 1 | 2014 | 3846 | 0.010 |
Why?
|
| Mutation | 1 | 2018 | 15904 | 0.010 |
Why?
|
| Adolescent | 1 | 2017 | 32784 | 0.010 |
Why?
|
| Retrospective Studies | 1 | 2019 | 39951 | 0.010 |
Why?
|